Advancing Synovial Sarcoma Care: Exploring Innovations in Targeted Therapies - Episode 7
A panelist discusses how afamitresgene autoleucel (afami-cel) therapy could be optimally sequenced after first- or second-line standard treatments while patients maintain good functional status, though the exact positioning would depend on individual patient factors, such as MAGE-A4 expression levels, prior therapy responses, and overall clinical condition.
Video content above is prompted by the following: